| Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire … G Damaj, A Duhamel, M Robin, Y Beguin, M Michallet, M Mohty, ... Journal of clinical oncology 30 (36), 4533-4540, 2012 | 259 | 2012 |
| Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations B Mohty, J El-Cheikh, I Yakoub-Agha, P Moreau, JL Harousseau, M Mohty haematologica 95 (2), 311-319, 2010 | 240 | 2010 |
| Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide L Castagna, R Crocchiolo, S Furst, S Bramanti, J El Cheikh, B Sarina, ... Biology of Blood and Marrow Transplantation 20 (5), 724-729, 2014 | 178 | 2014 |
| Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia G Battipaglia, A Ruggeri, R Massoud, J El Cheikh, M Jestin, A Antar, ... Cancer 123 (15), 2867-2874, 2017 | 118 | 2017 |
| Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells M Lioznov, J El-Cheikh, F Hoffmann, Y Hildebrandt, F Ayuk, C Wolschke, ... Bone marrow transplantation 45 (2), 349-353, 2010 | 117 | 2010 |
| Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’approaches in the era of novel agents B Mohty, J El-Cheikh, I Yakoub-Agha, H Avet-Loiseau, P Moreau, ... Leukemia 26 (1), 73-85, 2012 | 109 | 2012 |
| Haploidentical T cell–replete transplantation with post-transplantation cyclophosphamide for patients in or above the sixth decade of age compared with allogeneic hematopoietic … D Blaise, S Fürst, R Crocchiolo, J El-Cheikh, A Granata, S Harbi, ... Biology of Blood and Marrow Transplantation 22 (1), 119-124, 2016 | 105 | 2016 |
| CD34+-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies E Klyuchnikov, J El-Cheikh, A Sputtek, M Lioznov, B Calmels, S Furst, ... Biology of blood and marrow transplantation 20 (3), 382-386, 2014 | 99 | 2014 |
| Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party M Sobh, M Michallet, G Gahrton, S Iacobelli, A van Biezen, S Schönland, ... Leukemia 30 (10), 2047-2054, 2016 | 85 | 2016 |
| Sequential conditioning with thiotepa in T cell-replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with … R Duléry, AL Ménard, S Chantepie, J El-Cheikh, S François, J Delage, ... Biology of Blood and Marrow Transplantation 24 (5), 1013-1021, 2018 | 81 | 2018 |
| Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma H De Lavallade, J El-Cheikh, C Faucher, S Fürst, AM Stoppa, D Coso, ... Bone marrow transplantation 41 (11), 953-960, 2008 | 80 | 2008 |
| Rituximab as salvage therapy for refractory chronic GVHD M Mohty, N Marchetti, J El-Cheikh, C Faucher, S Fürst, D Blaise Bone marrow transplantation 41 (10), 909-911, 2008 | 77 | 2008 |
| Risk factors of G anciclovir‐related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients G Venton, R Crocchiolo, S Fürst, A Granata, C Oudin, C Faucher, D Coso, ... Clinical Microbiology and Infection 20 (2), 160-166, 2014 | 73 | 2014 |
| High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for … J El-Cheikh, M Michallet, A Nagler, H De Lavallade, FE Nicolini, ... Haematologica 93 (3), 455-458, 2008 | 73 | 2008 |
| The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies … R Devillier, R Crocchiolo, L Castagna, S Fürst, J El Cheikh, C Faucher, ... Bone marrow transplantation 47 (5), 639-645, 2012 | 71 | 2012 |
| Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party A Bazarbachi, M Labopin, G Battipaglia, A Djabali, J Passweg, G Socié, ... Haematologica 104 (9), e398, 2019 | 69 | 2019 |
| Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft‐versus‐host disease in reduced‐intensity conditioning transplantation for … R Crocchiolo, B Esterni, L Castagna, S Fürst, J El‐Cheikh, R Devillier, ... Cancer 119 (5), 986-992, 2013 | 68 | 2013 |
| Inhibition of FLT3 in AML: a focus on sorafenib A Antar, ZK Otrock, J El-Cheikh, MA Kharfan-Dabaja, G Battipaglia, ... Bone marrow transplantation 52 (3), 344-351, 2017 | 67 | 2017 |
| Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma L Castagna, S Bramanti, R Devillier, B Sarina, R Crocchiolo, S Furst, ... Bone marrow transplantation 52 (5), 683-688, 2017 | 65 | 2017 |
| Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’versus ‘no donor’comparison M Mohty, H De Lavallade, J El-Cheikh, P Ladaique, C Faucher, S Fürst, ... Leukemia 23 (1), 194-196, 2009 | 65 | 2009 |
Didier BlaiseProfesseur de Medecine, Université Aix Marseille, Institut Paoli CalmettesZweryfikowany adres z ipc.unicancer.fr
